Cargando…

Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model

Due to the complex mechanisms affecting anti-tumor immune response, a single biomarker is insufficient to identify patients who will benefit from immune checkpoint inhibitors (ICIs) treatment. Therefore, a comprehensive predictive model is urgently required to predict the response to ICIs. A total o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lei, Zhang, Hongbing, Pan, Chaohu, Yi, Jian, Cui, Xiaoli, Li, Na, Wang, Jiaqian, Gao, Zhibo, Wu, Dongfang, Chen, Jun, Jiang, Jizong, Chu, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072668/ https://www.ncbi.nlm.nih.gov/pubmed/35529874 http://dx.doi.org/10.3389/fimmu.2022.829634

Ejemplares similares

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
por: Pan, Chaohu, et al.
Publicado: (2023)

Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors
por: Chen, Qian, et al.
Publicado: (2022)

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers
por: Li, Ye, et al.
Publicado: (2021)

Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report
por: Mari, Roxane, et al.
Publicado: (2022)

Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors
por: Ding, Lizhong, et al.
Publicado: (2023)

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
por: Qian, Xinye, et al.
Publicado: (2022)

Advances in CT features and radiomics of checkpoint inhibitor-related pneumonitis: A short review
por: Huang, Jie, et al.
Publicado: (2023)

Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians
por: Zhou, Huijie, et al.
Publicado: (2023)

Sex — a potential factor affecting immune checkpoint inhibitor therapy for cancers
por: Hu, Wang, et al.
Publicado: (2022)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhou, Jiaxin, et al.
Publicado: (2022)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zhang, Zhibo, et al.
Publicado: (2020)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
por: Zhou, Guanzhou, et al.
Publicado: (2022)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
por: Wu, Jianmin, et al.
Publicado: (2021)

Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer
por: Chen, Chen, et al.
Publicado: (2021)

Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
por: Xie, Xiaohong, et al.
Publicado: (2022)

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer
por: He, Jiahui, et al.
Publicado: (2023)

Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors
por: Liu, Wenhui, et al.
Publicado: (2021)

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022
por: Wang, Yanfeng, et al.
Publicado: (2023)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
por: Tang, Liansha, et al.
Publicado: (2021)

Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers
por: Wang, Jingting, et al.
Publicado: (2022)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
por: von Knethen, Andreas, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Cutaneous manifestations associated with immune checkpoint inhibitors
por: Watanabe, Tomoya, et al.
Publicado: (2023)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma
por: Liu, Rongrong, et al.
Publicado: (2022)

Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
por: Cao, Ting, et al.
Publicado: (2023)

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
por: Zhou, Kexun, et al.
Publicado: (2023)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review
por: Pan, Lei, et al.
Publicado: (2023)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments
por: Liao, Ping, et al.
Publicado: (2023)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5j68q0ko3gh7f7731pv7h75tkn